MCRB

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a microbiome therapeutics platform company founded in 2010 and headquartered in Cambridge, Massachusetts. The company was originally incorporated as Seres Health, Inc. before changing its name in May 2015, the same year it went public. Seres focuses on developing bacterial consortia designed to functionally interact with host cells and tissues to treat various diseases. The company has undergone significant strategic transformation in recent years, including the sale of its first approved product VOWST to Nestlé Health Science in 2024 for $155 million, allowing it to focus on its pipeline of live biotherapeutic products for preventing infections in medically vulnerable patient populations.